Exchange: NASDAQ·Updated 07:30 PM EST

RTSN Retension Pharmaceuticals Inc.

$10.51
$2.50
(19.22%)
Today
Closed $10.51
$0.00
(0.00%)
After Hours
Reported EarningsNov 18
Mkt Cap$93.48M
Vol162,743.00

About RTSN

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
48

Neutral Sentiment

How do you feel about RTSN?

Advertisement|Remove ads.